Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 216

The DOI matches its Crossref record.

Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis

Open access
Tamirou, Farah, D'Cruz, David, Sangle, Shirish, Remy, Philippe, Vasconcelos, Carlos, Fiehn, Christoph, Ayala Guttierez, Maria del Mar, Gilboe, Inge-Magrethe, Tektonidou, Maria, Blockmans, Daniel, Ravelingien, Isabelle, le Guern, Véronique, Depresseux, Geneviève, Guillevin, Loïc, Cervera, Ricard, Houssiau, Frédéric A·2016·Annals of the Rheumatic Diseases

Abstract

OBJECTIVE: To report the 10-year follow-up of the MAINTAIN Nephritis Trial comparing azathioprine (AZA) and mycophenolate mofetil (MMF) as maintenance therapy of proliferative lupus nephritis, and to test different definitions of early response as predictors of long-term renal outcome. METHODS: In 2014, data on survival, kidney function, 24 h proteinuria, renal flares and other outcomes were collected for the 105 patients randomised between 2002 and 2006, except in 13 lost to follow-up. RESULTS: Death (2 and 3 in the AZA and MMF groups, respectively) and end-stage renal disease (1 and 3, respectively) were rare events. Time to renal flare (22 and 19 flares in AZA and MMF groups, respectively) did not differ between AZA and MMF patients. Patients with good long-term renal outcome had a much more stringent early decrease of 24 h proteinuria compared with patients with poor outcome. The positive predictive value of a 24 h proteinuria <0.5 g/day at 3 months, 6 months and 12 months for a good long-term renal outcome was excellent (between 89% and 92%). Inclusion of renal function and urinalysis in the early response criteria did not impact the value of early proteinuria decrease as long-term prognostic marker. CONCLUSIONS: The long-term follow-up data of the MAINTAIN Nephritis Trial do not indicate that MMF is superior to AZA as maintenance therapy in a Caucasian population suffering from proliferative lupus nephritis. Moreover, we confirm the excellent positive predictive value of an early proteinuria decrease for long-term renal outcome. TRIAL REGISTRATION NUMBER: NCT00204022.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2014-206897

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 216

Metadata

Authors
Tamirou, F., D'Cruz, D., Sangle, S., Remy, P., Vasconcelos, C., Fiehn, C., Ayala Guttierez, M. D. M., Gilboe, I.-M., Tektonidou, M., Blockmans, D., Ravelingien, I., le Guern, V., Depresseux, G., Guillevin, L., Cervera, R., & Houssiau, F. A.
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2016-03
Volume
75
Issue
3
Pages
526-531
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2161335088
Cited by
216
References
0
FWCI
14.83
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. https://app.cochat.ai/papers/10.1136/annrheumdis-2014-206897
The paper
Tamirou, F., D'Cruz, D., Sangle, S., Remy, P., Vasconcelos, C., Fiehn, C., Ayala Guttierez, M. D. M., Gilboe, I.-M., Tektonidou, M., Blockmans, D., Ravelingien, I., le Guern, V., Depresseux, G., Guillevin, L., Cervera, R., & Houssiau, F. A. (2016). Long-term follow-up of the MAINTAIN Nephritis Trial, comparing azathioprine and mycophenolate mofetil as maintenance therapy of lupus nephritis. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2014-206897

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.